Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of intranasal zavegepant for acute migraine
NCT04408794Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jun 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of zavegepant in migraine, sponsored by Pfizer. Started Jun 2020; status: completed.
02
Drugs
zavegepant
03
Conditions
migraine
Beyond the preview
Go deeper on NCT04408794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04408794.